Product Information

CAS No.	936694-12-1
Product Name	Glesatinib

Biological Targets

MET·MST1R·TEK·FLT1·FLT4·

Associated Conditions

non-small cell lung carcinoma·cancer

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Journal of medicinal chemistry • Vol. 60, Issue 17 • 2017

PMID: 28787156 DOI: 10.1021/acs.jmedchem.7b00794

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 23, Issue 21 • 2017

PMID: 28765324 DOI: 10.1158/1078-0432.CCR-17-1192

Targeting the Met pathway in lung cancer.

Expert review of anticancer therapy • Vol. 12, Issue 4 • 2012

PMID: 22500688 DOI: 10.1586/era.12.16

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Bioorganic & medicinal chemistry letters • Vol. 18, Issue 9 • 2008

PMID: 18434145 DOI: 10.1016/j.bmcl.2008.04.009

Glesatinib

CAS No.	936694-12-1
MDL No.	N/A
MF	C₃₁H₂₇F₂N₅O₃S₂
MW	619.70
InChI Key	YRCHYHRCBXNYNU-UHFFFAOYSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	936694-12-1
Product Name	Glesatinib

Biological Targets

MET·MST1R·TEK·FLT1·FLT4·

Associated Conditions

non-small cell lung carcinoma·cancer

* The information provided here is compiled from public sources and is for reference only.

Glesatinib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Glesatinib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Glesatinib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Targeting the Met pathway in lung cancer.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Similar Products

Sitravatinib

Glesatinib

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.

Targeting the Met pathway in lung cancer.

Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.

Similar Products

Sitravatinib

Documentation